Board of Directors
Steven James (Executive Chairman)
Steven James serves as Executive Chairman of Antiva Biosciences’ Board of Directors. Mr. James is a veteran biotech CEO, having led KAI Pharmaceuticals to its acquisition by Amgen and most recently, Labrys Biologics, which was acquired by Teva. Currently, he sits on the boards of Ocera, Inc., Chrono Therapeutics, Allakos, Inc., Cascadian Therapeutics, and Precision Immune Inc.
Michael Cannon has over forty years of experience in the pharmaceutical industry. He worked for twenty years at SICOR, a Swiss-Italian API manufacturing company, in a variety of positions in manufacturing, quality and regulatory affair before moving to business development. He was a member of the team that conducted the merger of SICOR with Gensia of San Diego in 1997. He served as a member of SICOR’s board and president of the biotech division until the company was sold to Teva in 2004. Mr. Cannon is now a board member of Waterstone, a Chinese pharmaceutical company, as well as Osel and BioSentinel, both in the US.
General Partner, Canaan Partners
Wende Hutton has over 23 years of experience in healthcare venture capital and has been a General Partner at Canaan Partners since 2004. Ms. Hutton currently sits on the boards of Antiva Biosciences, Chrono Therapeutics, Glooko, ReVision Optics and OncoResponse. She has been an investor and board member at dozens of medical technology and biopharmaceutical companies including BiPar Sciences (acquired by Sanofi-aventis), Chimerix (CMRX), Dermira (DERM), Labrys Biologics (acquired by Teva Pharmaceutical), and Transcend Medical (acquired by Alcon/Novartis).
David Kabakoff, PhD
Executive Partner, Sofinnova Ventures
David Kabakoff, PhD has 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields. He joined Sofinnova Ventures as an Executive Partner in 2007. He currently serves as Chairman of Lineagen, Inc. and NextCure, Inc. He is also a Director of Dauntless Pharmacueticals and serves as a Board Observer at Castle Biosciences. Dr. Kabakoff co-founded Salmedix, Inc., a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer. In June 2005, he negotiated the acquisition of Salmedix by Cephalon, Inc. Dr. Kabakoff also held the positions of Executive Vice President of Dura Pharmaceuticals and President and Chief Executive Officer of Spiros Development Corp.
President & CEO, Brace Pharma Capital
Vinzenz Ploerer has 30+ years of extensive leadership experience in operations, acquisitions and business development and currently serves on several life science company boards. Prior to launching Brace, he worked at EMS S/A as Senior Vice President of Strategy and Operations. He has held various leadership positions at Novartis/Sandoz including country head of Brazil, Argentina and Head of BDL Sandoz, building the company through acquisitions. Mr. Ploerer holds an M.B.A. in Strategy from Leopold-Franzens Universität Innsbruck, participated in Novartis Leadership Program at Harvard Business School, and attended the Advance Management Program at Insead Fontainbleau.
Benjamin Rovinski, PhD
Managing Director, Lumira Capital
Benjamin Rovinski has 28 years of investment, operational, managerial and research experience in the healthcare sector, including 13 years at Sanofi Pasteur, where he led global R&D programs in areas such as HIV/AIDS and therapeutic cancer vaccines. He received a PhD in biochemistry from McGill University in Montréal and did post-doctoral studies in molecular oncology and retrovirology at the Ontario Cancer Institute in Toronto. Beni joined Lumira Capital in 2001 and his current and past board roles include G1 Therapeutics (NASDAQ: GTHX); Aurinia Pharmaceuticals (NASDAQ: AUPH); KAI Pharmaceuticals (acquired by Amgen); Morphotek (acquired by Eisai); Health Hero Network (acquired by Bosch); Avalon Pharmaceuticals (NASDAQ: AVRX; acquired by Clinical Data, Inc.); and SGX Pharmaceuticals (NASDAQ: SGXP; acquired by Eli Lilly).
President & CEO, Antiva Biosciences
Gail Maderis brings over 20 years of leadership in biopharmaceutical companies to the Antiva team. From 2009 to 2015, Gail led BayBio, the industry organization representing and supporting Northern California’s life science community. From 2003 to 2009, Gail served as President and CEO of Five Prime Therapeutics, Inc., a protein discovery and development company. At FivePrime, she successfully funded the company’s rapid growth through substantial private equity financings and corporate partnerships and took the company’s first novel cancer therapeutic from discovery into clinical trials. Prior to FivePrime, Gail held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Gail also practiced management and strategy consulting with Bain & Co. She currently serves on the boards of NovaBay Pharmaceuticals (NBY) and Opexa Therapeutics (OPXA). She received a BS in business from UC Berkeley and an MBA from Harvard Business School.